ReviewGeroScience2025
White matter lesions contribute to motor and non-motor disorders in Parkinson's disease: a critical review.
Review in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Temporal Mapping of CSVD-Related White Matter Lesions and Concurrent Neurovascular Dysfunction in Spontaneously Hypertensive Rats.CNS neuroscience & therapeutics · 2026Article
- Integrating retinal and brain imaging biomarkers for diagnosis of parkinson's disease: findings from a time-lagged cross-sectional persian cohort study.Scientific reports · 2026Article
- Spatiotemporal profiling of white matter lesions and their contribution in the pathologies of Parkinson's disease animal models.GeroScience · 2026Article
- AI-Assisted Self-Powered Wearable Dual-Mode Sensor With TENG and Stretchable Optical Fiber for Neurological Disorder Diagnostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- In-vivo histology of Parkinson's disease using quantitative multiparametric mapping.NPJ Parkinson's disease · 2026Article
- Enhancing oligodendrocytes generation and myelin renewal by vitamin C mitigate Parkinson-relevant phenotypes in a murine model of Parkinson's disease.Frontiers in cellular neuroscience · 2026Article
- Nervonic Acid fromBiomaterials research · 2026Article
- Review
- Preserved white matter integrity is a promising indicator of cognitive resilience in Parkinson's disease.Scientific reports · 2025Article
- Targeting HDAC3 Suppresses Ferroptosis and Demyelination in White Matter Injury by Restoring PDK4-Mediated Iron Homeostasis.CNS neuroscience & therapeutics · 2025Article
- Functional remapping in networks of the Parkinsonian brain: A preclinical neuroimaging perspective with clinical correlates.Translational neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Parkinson's disease (PD) is a prevalent neurodegenerative disease, characterized by movement disorders and non-motor symptoms like cognitive impairment and depression. Degeneration of dopaminergic neurons in the substantia nigra and Lewy bodies have long been considered as main neuropathological changes. However, recent magnetic resonance imaging (MRI) studies have shown that white matter lesions (WMLs) were present in PD patients. WMLs are characterized by loss or impairment of myelin sheath in central nerve fibers, which are closely correlated with motor and cognitive dysfunction in PD. WMLs alterations precede nigrostriatal neuronal losses and can independently affect the clinical severity or characteristics of motor coordination in PD patients. Currently, the exact mechanism of WMLs involvement in the occurrence and development of PD remains unclear. It is speculated that WMLs may participate in the pathogenesis of PD by disrupting important connections in brain or promoting axonal degeneration. In this review, we will discuss the pathological changes and mechanisms of WMLs, elaborate the impact of WMLs on the progression of PD, clarify the importance of WMLs in PD pathogenesis, and thus provide novel targets for PD treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.